异基因造血干细胞移植后急性髓系白血病复发:机制多样性与治疗方向
本综述通过汇编支持性研究,描述异基因造血干细胞移植后急性髓系白血病复发的机制及其对后续治疗选择的影响。文章指出克隆演化与耐药白血病株出现是化疗后和移植后复发的共同机制,而白血病免疫逃逸和供者T细胞耗竭为移植后复发所特有。由于机制多样,后续临床方案依赖临床医生判断而非客观证据,缺乏基于复发机制的标准化选择可能是预后不佳的因素之一。
要点
- 移植后复发机制多样,克隆演化与耐药株出现是化疗后和移植后复发的共同机制。
- 白血病免疫逃逸和供者T细胞耗竭为移植后复发所特有。
- 供者淋巴细胞输注、二次移植、免疫治疗、去甲基化药物和靶向策略为支持性选择。
核心结论
- 移植后急性髓系白血病复发机制多样,明确机制可能指导治疗选择并提升疗效。
- 缺乏基于移植后复发机制的标准化选择可能是观察到的预后不佳的贡献因素。
研究设计与样本
- 综述,通过汇编支持性研究描述移植后复发机制及其对后续治疗选择和未来研究的启示。
主要发现
- 克隆演化和耐药白血病株出现是化疗后和移植后复发共有的常见机制。
- 白血病免疫逃逸和供者T细胞耗竭是移植后复发特有的机制。
- 由于移植后复发机制多样,后续临床方案依赖临床医生判断而非客观证据。
临床怎么用
- 供者淋巴细胞输注、二次移植、免疫治疗、去甲基化药物和靶向策略为支持性选择。
- 当移植后急性髓系白血病复发机制明确并指导治疗选择时,疗效可能增强。
- 后续临床方案依赖临床医生判断而非客观证据,原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging biological and clinical data, along with advances in new technologies, have exposed the mechanistic diversity in post-haematopoietic stem cell transplant (HCT) relapse. Post-HCT relapse mechanisms are relevant for guiding sophisticated selection of therapeutic interventions and identification of areas for further research. Clonal evolution and emergence of resistant leukemic strains is a common mechanism shared by relapse post-chemotherapy and post-HCT, other mechanisms such as leukemic immune escape and donor T cell exhaustion are unique entities to post-HCT relapse. Due to diversity in the mechanisms behind post-HCT relapse, the subsequent clinical approach relies on clinician discretion, rather than objective evidence. Lack of standardized selection based on post-HCT relapse mechanism(s) could be a contributing factor to observed poor outcomes. Therapeutic strategies including donor lymphocyte infusion (DLI), second transplant, immunotherapies, hypomethylating agents, and targeted strategies are supported options and efficacy may be enhanced when post-HCT AML relapse mechanism is established and guides treatment selection. This review aims, through compilation of supporting studies, to describe mechanisms of post-HCT relapse and their implications for subsequent treatment selection and inspiration for future research.
引用
- Herrity E, Pereira MP, Kim DDH, et al. Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions. Br J Haematol. 2023. PMID: 37787151. doi:10.1111/bjh.19121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。